The FDA recently approved several abbreviated new drug applications (ANDAs), effectively introducing many first-time generic drugs to the market. Many of the drugs approved are utilized in workers’ comp, meaning there are now therapeutic alternatives available for patients at reduced costs.
Recent generic approvals impacting workers’ comp include:
- Prezista® (darunavir) tablets for the treatment of HIV-1 infection. As needlestick injuries can expose healthcare workers to HIV, HIV medications have seen semiregular use in workers’ comp
- Byvalson® (nebivolol and valsartan) tablets for the treatment of hypertension to lower blood pressure. As hypertension is a common comorbidity in workers’ comp claims, managing hypertension can benefit claims outcomes
- Tazorac® (tazarotene) gel for the topical treatment of plaque psoriasis. Physical overexertion can trigger pre-existing psoriatic conditions, leading to the prescribing of psoriasis medications. Additionally, skin infections can occur if exposed to excessive heat or cold, fungal or bacterial contaminants, or allergens
- Dalirsep® (roflumilast) tablets to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD. COPD can be an occupational illness for coal and mill workers, among many other occupations
- Banzel® (rufinamide) tablets for the treatment of seizures associated with Lennox-Gastaut Syndrome. While this disease is thought to be genetic, it can be triggered by severe head injury
- Rexulti® (brexpiprazole) tablets for the treatment of major depressive disorder
- Jardiance® (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes
For ongoing coverage of the latest drug approvals and alerts impacting workers’ comp, visit Med Monitor online.
Tags: drug approvals, FDA, generic drugs
